Last reviewed · How we verify

NCT03089619

Alveolar Management Following Teeth Extraction

Terminated Phase 4 Last updated 17 July 2023
What this trial tests

Phase 4 trial testing Human-Spongiosa in Alveolar Bone Loss in 21 participants. Terminated before completion.

Timeline
2 May 2016
Primary endpoint
14 January 2022
8 May 2023

Quick facts

Lead sponsorUniversity Medicine Greifswald
PhasePhase 4
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment21
Start date2 May 2016
Primary completion14 January 2022
Estimated completion8 May 2023
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Medicine Greifswald

Who can join

Adults 20 to 60, any sex, with Alveolar Bone Loss or Bone Resorption. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation of the volume stability of the alveolar ridge, the bone structure and soft tissue appearance at a delayed dental implantation using two bone substitute materials (1. Human-Spongiosa, gefriergetrocknet, CHB; 2. collacone®)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alveolar Bone Loss

Currently open trials in the same condition.

Other University Medicine Greifswald trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03089619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing